A clinical trial investigating the effect of ATO in combination with thalidomide in myelodysplastic syndrome (MDS), reported hematologic responses in three out of five patients with overexpression of EVI1, including responses in two out of three patients with inv(3)/t(3;3) (Raza et al., 2004). The gene discussed is MECOM; the disease is myelodysplastic syndrome.